Efficacy and safety of ferric carboxymaltose in anemia in pregnancy

Abstract

To study the role, safety and efficacy of ferric carboxymaltose in antenatal women. Methodology: This will be a prospective interventional study conducted in Obstetrics and Gynaecology department of AMC MET medical college. Study group of 40 antenatal women between 20 weeks to 32 weeks of gestation will be followed through. Haemoglobin level before infusion of FCM and after 2 weeks of infusion will be estimated. The efficacy of ferric carboxymaltose will be analysed in study group. The evaluation of safety and tolerance to mother will also be monitored. Inclusion criteria: Gestational age > 20 weeks and < 32 weeks, Haemoglobin concentration of > 6 gm% and < 8 gm%. Exclusion criteria: Hypersensitivity reaction to any iron preparation, History of blood transfusion, History of iron overload diseases, Concomitant medical or surgical diseases. Results: A total of 40 antenatal patients were included in our study. It's observed that the incidence of anaemia was higher among the reproductive age group especially in pregnant women of 21 to 30 years of age, than so in age group less than 20 and more than 30. Out of which 35% were primigravida and 65% were multigravida. Among 40 patients who received Inj. Ferric carboxylate maltose, 3 patients developed drug reactions. The mean rise in haemoglobin was found to be 0.9gm/dl at the end of 15 days from treatment. Correspondingly the MCV and RDW values were up by 11fL and 4.3% respectively. Conclusion:Ferric carboxymaltose is a safe and effective treatment option for iron deficiency anaemia in antenatal patients.

Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnancy: A Subgroup Analysis of a Multicenter Real-World Study Involving 1191 Pregnant Women

“…Tere is abundant clinical evidence supporting the effective and safe use of IV FCM for correcting anemia and replenishing iron stores during pregnancy [12][13][14][15][16][17][18][19][20][21][22][23][24]. Also, compared to other parenteral iron preparations, IV FCM reported rapid correction of anemia during pregnancy [12][13][14][15][16][17][18][19][20][21][22][23][24]. Further, a large FCM dose (1000 mg) can be administered in a single setting with good efcacy and minimal adverse efects [12, 14-16, 21, 23, 24, 27].…”

“…Ferric carboxymaltose (FCM) is a third-generation parenteral iron formulation used for correcting IDA. Tere are many Indian [12][13][14][15][16][17][18][19][20] and international [21][22][23][24] clinical studies supporting the efcacy and safety of FCM in treating IDA in pregnancy. However, there is limited real-world evidence (RWE) [25][26][27][28][29] reporting the efcacy and safety of FCM in pregnancy and particularly in India.…”

Evaluation of the effectiveness of the use of iron carboxymaltosate in late pregnancy and in the postpartum period

“…• неблагоприятная наследственность; • короткие промежутки между родами. Диагноз «анемия» ставится на основании комплекса диагностических критериев (снижение уровня Hb, ферритина, повышение уровня трансферрина, снижение коэффициента насыщения трансферрина железом на фоне повышения общей железосвязывающей способности сыворотки крови) [8][9][10].…”